These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

220 related items for PubMed ID: 20622144

  • 1. Methamphetamine-induced dopamine transporter complex formation and dopaminergic deficits: the role of D2 receptor activation.
    Hadlock GC, Chu PW, Walters ET, Hanson GR, Fleckenstein AE.
    J Pharmacol Exp Ther; 2010 Oct; 335(1):207-12. PubMed ID: 20622144
    [Abstract] [Full Text] [Related]

  • 2. Mechanisms underlying methamphetamine-induced dopamine transporter complex formation.
    Hadlock GC, Baucum AJ, King JL, Horner KA, Cook GA, Gibb JW, Wilkins DG, Hanson GR, Fleckenstein AE.
    J Pharmacol Exp Ther; 2009 Apr; 329(1):169-74. PubMed ID: 19141713
    [Abstract] [Full Text] [Related]

  • 3. Single and binge methamphetamine administrations have different effects on the levels of dopamine D2 autoreceptor and dopamine transporter in rat striatum.
    Chauhan H, Killinger BA, Miller CV, Moszczynska A.
    Int J Mol Sci; 2014 Apr 08; 15(4):5884-906. PubMed ID: 24717411
    [Abstract] [Full Text] [Related]

  • 4. Methamphetamine increases dopamine transporter higher molecular weight complex formation via a dopamine- and hyperthermia-associated mechanism.
    Baucum AJ, Rau KS, Riddle EL, Hanson GR, Fleckenstein AE.
    J Neurosci; 2004 Mar 31; 24(13):3436-43. PubMed ID: 15056723
    [Abstract] [Full Text] [Related]

  • 5.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 6. Methamphetamine alters vesicular monoamine transporter-2 function and potassium-stimulated dopamine release.
    Chu PW, Hadlock GC, Vieira-Brock P, Stout K, Hanson GR, Fleckenstein AE.
    J Neurochem; 2010 Oct 31; 115(2):325-32. PubMed ID: 20649837
    [Abstract] [Full Text] [Related]

  • 7. Prior methamphetamine self-administration attenuates the dopaminergic deficits caused by a subsequent methamphetamine exposure.
    McFadden LM, Vieira-Brock PL, Hanson GR, Fleckenstein AE.
    Neuropharmacology; 2015 Jun 31; 93():146-54. PubMed ID: 25645392
    [Abstract] [Full Text] [Related]

  • 8. Methamphetamine-induced rapid decrease in dopamine transporter function: role of dopamine and hyperthermia.
    Metzger RR, Haughey HM, Wilkins DG, Gibb JW, Hanson GR, Fleckenstein AE.
    J Pharmacol Exp Ther; 2000 Dec 31; 295(3):1077-85. PubMed ID: 11082443
    [Abstract] [Full Text] [Related]

  • 9. Bupropion increases striatal vesicular monoamine transport.
    Rau KS, Birdsall E, Hanson JE, Johnson-Davis KL, Carroll FI, Wilkins DG, Gibb JW, Hanson GR, Fleckenstein AE.
    Neuropharmacology; 2005 Nov 31; 49(6):820-30. PubMed ID: 16005476
    [Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12. A rapid oxidation and persistent decrease in the vesicular monoamine transporter 2 after methamphetamine.
    Eyerman DJ, Yamamoto BK.
    J Neurochem; 2007 Nov 31; 103(3):1219-27. PubMed ID: 17683483
    [Abstract] [Full Text] [Related]

  • 13. Environmental enrichment reduces methamphetamine cue-induced reinstatement but does not alter methamphetamine reward or VMAT2 function.
    Hofford RS, Darna M, Wilmouth CE, Dwoskin LP, Bardo MT.
    Behav Brain Res; 2014 Aug 15; 270():151-8. PubMed ID: 24821405
    [Abstract] [Full Text] [Related]

  • 14. Immunohistochemical investigation of dopaminergic terminal markers and caspase-3 activation in the striatum of human methamphetamine users.
    Kitamura O, Tokunaga I, Gotohda T, Kubo S.
    Int J Legal Med; 2007 May 15; 121(3):163-8. PubMed ID: 16622715
    [Abstract] [Full Text] [Related]

  • 15. Methamphetamine self-administration acutely decreases monoaminergic transporter function.
    McFadden LM, Stout KA, Vieira-Brock PL, Allen SC, Nielsen SM, Wilkins DG, Hanson GR, Fleckenstein AE.
    Synapse; 2012 Mar 15; 66(3):240-5. PubMed ID: 22120988
    [Abstract] [Full Text] [Related]

  • 16. A history of ethanol drinking increases locomotor stimulation and blunts enhancement of dendritic dopamine transmission by methamphetamine.
    Tschumi CW, Daszkowski AW, Sharpe AL, Trzeciak M, Beckstead MJ.
    Addict Biol; 2020 Jul 15; 25(4):e12763. PubMed ID: 31062485
    [Abstract] [Full Text] [Related]

  • 17. Regional heterogeneity of dopaminergic deficits in vervet monkey striatum and substantia nigra after methamphetamine exposure.
    Harvey DC, Laćan G, Melegan WP.
    Exp Brain Res; 2000 Aug 15; 133(3):349-58. PubMed ID: 10958525
    [Abstract] [Full Text] [Related]

  • 18. Methylenedioxymethamphetamine decreases plasmalemmal and vesicular dopamine transport: mechanisms and implications for neurotoxicity.
    Hansen JP, Riddle EL, Sandoval V, Brown JM, Gibb JW, Hanson GR, Fleckenstein AE.
    J Pharmacol Exp Ther; 2002 Mar 15; 300(3):1093-100. PubMed ID: 11861820
    [Abstract] [Full Text] [Related]

  • 19. HIV-1 Tat protein decreases dopamine transporter cell surface expression and vesicular monoamine transporter-2 function in rat striatal synaptosomes.
    Midde NM, Gomez AM, Zhu J.
    J Neuroimmune Pharmacol; 2012 Sep 15; 7(3):629-39. PubMed ID: 22570010
    [Abstract] [Full Text] [Related]

  • 20. Methamphetamine-induced alterations in dopamine transporter function.
    Bennett BA, Hollingsworth CK, Martin RS, Harp JJ.
    Brain Res; 1998 Jan 26; 782(1-2):219-27. PubMed ID: 9519266
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 11.